These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8817830)

  • 81. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
    Murphy SC; Deye GA; Sim BKL; Galbiati S; Kennedy JK; Cohen KW; Chakravarty S; Kc N; Abebe Y; James ER; Kublin JG; Hoffman SL; Richie TL; Jackson LA
    PLoS Pathog; 2021 May; 17(5):e1009594. PubMed ID: 34048504
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover.
    Wijayalath W; Cheesman S; Tanabe K; Handunnetti S; Carter R; Pathirana S
    PLoS One; 2012; 7(9):e45861. PubMed ID: 23029282
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP).
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934676. PubMed ID: 34511592
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission.
    Tall A; Sokhna C; Perraut R; Fontenille D; Marrama L; Ly AB; Sarr FD; Toure A; Trape JF; Spiegel A; Rogier C; Druilhe P
    Malar J; 2009 Jul; 8():161. PubMed ID: 19604389
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites.
    Finney OC; Keitany GJ; Smithers H; Kaushansky A; Kappe S; Wang R
    Vaccine; 2014 Apr; 32(19):2135-8. PubMed ID: 24582635
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.
    Kublin JG; Lowitt MH; Hamilton RG; Oliveira GA; Nardin EH; Nussenzweig RS; Schmeckpeper BJ; Diggs CL; Bodison SA; Edelman R
    Vaccine; 2002 Mar; 20(13-14):1853-61. PubMed ID: 11906775
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.
    Richie TL; Billingsley PF; Sim BK; James ER; Chakravarty S; Epstein JE; Lyke KE; Mordmüller B; Alonso P; Duffy PE; Doumbo OK; Sauerwein RW; Tanner M; Abdulla S; Kremsner PG; Seder RA; Hoffman SL
    Vaccine; 2015 Dec; 33(52):7452-61. PubMed ID: 26469720
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A genetically engineered
    Murphy SC; Vaughan AM; Kublin JG; Fishbauger M; Seilie AM; Cruz KP; Mankowski T; Firat M; Magee S; Betz W; Kain H; Camargo N; Haile MT; Armstrong J; Fritzen E; Hertoghs N; Kumar S; Sather DN; Pinder LF; Deye GA; Galbiati S; Geber C; Butts J; Jackson LA; Kappe SHI
    Sci Transl Med; 2022 Aug; 14(659):eabn9709. PubMed ID: 36001680
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine.
    Webster R; Sekuloski S; Odedra A; Woolley S; Jennings H; Amante F; Trenholme KR; Healer J; Cowman AF; Eriksson EM; Sathe P; Penington J; Blanch AJ; Dixon MWA; Tilley L; Duffy MF; Craig A; Storm J; Chan JA; Evans K; Papenfuss AT; Schofield L; Griffin P; Barber BE; Andrew D; Boyle MJ; de Labastida Rivera F; Engwerda C; McCarthy JS
    BMC Med; 2021 Nov; 19(1):293. PubMed ID: 34802442
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.
    Edelman R; Wasserman SS; Kublin JG; Bodison SA; Nardin EH; Oliveira GA; Ansari S; Diggs CL; Kashala OL; Schmeckpeper BJ; Hamilton RG
    Vaccine; 2002 Dec; 21(3-4):269-80. PubMed ID: 12450702
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial.
    Nouatin O; Ibáñez J; Fendel R; Ngoa UA; Lorenz FR; Dejon-Agobé JC; Edoa JR; Flügge J; Brückner S; Esen M; Theisen M; Hoffman SL; Moutairou K; Luty AJF; Lell B; Kremsner PG; Adegnika AA; Mordmüller B
    Malar J; 2022 Jun; 21(1):191. PubMed ID: 35715803
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial.
    Lyke KE; Laurens M; Adams M; Billingsley PF; Richman A; Loyevsky M; Chakravarty S; Plowe CV; Sim BK; Edelman R; Hoffman SL
    PLoS One; 2010 Oct; 5(10):e13490. PubMed ID: 21042404
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.
    Thompson HA; Hogan AB; Walker PGT; White MT; Cunnington AJ; Ockenhouse CF; Ghani AC
    Vaccine; 2020 Nov; 38(47):7498-7507. PubMed ID: 33041104
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Plasmodium falciparum pre-erythrocytic stage vaccine development.
    Molina-Franky J; Cuy-Chaparro L; Camargo A; Reyes C; Gómez M; Salamanca DR; Patarroyo MA; Patarroyo ME
    Malar J; 2020 Feb; 19(1):56. PubMed ID: 32013956
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine.
    Hoffman SL; Cannon LT; Berzofsky JA; Majarian WR; Young JF; Maloy WL; Hockmeyer WT
    Exp Parasitol; 1987 Aug; 64(1):64-70. PubMed ID: 2440712
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adherence to chemoprophylaxis and Plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers.
    Belderok SM; van den Hoek A; Roeffen W; Sauerwein R; Sonder GJ
    PLoS One; 2013; 8(2):e56863. PubMed ID: 23451100
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers.
    Lawrence G; Cheng QQ; Reed C; Taylor D; Stowers A; Cloonan N; Rzepczyk C; Smillie A; Anderson K; Pombo D; Allworth A; Eisen D; Anders R; Saul A
    Vaccine; 2000 Mar; 18(18):1925-31. PubMed ID: 10699342
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.
    Jongo SA; Church LWP; Mtoro AT; Schindler T; Chakravarty S; Ruben AJ; Swanson PA; Kassim KR; Mpina M; Tumbo AM; Milando FA; Qassim M; Juma OA; Bakari BM; Simon B; James ER; Abebe Y; Kc N; Saverino E; Fink M; Cosi G; Gondwe L; Studer F; Styers D; Seder RA; Schindler T; Billingsley PF; Daubenberger C; Sim BKL; Tanner M; Richie TL; Abdulla S; Hoffman SL
    Clin Infect Dis; 2020 Dec; 71(11):2849-2857. PubMed ID: 31782768
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria.
    Wijayalath W; Majji S; Villasante EF; Brumeanu TD; Richie TL; Casares S
    Malar J; 2014 Sep; 13():386. PubMed ID: 25266106
    [TBL] [Abstract][Full Text] [Related]  

  • 100. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission.
    Teuscher T; Schellenberg JR; Bastos de Azevedo I; Hurt N; Smith T; Hayes R; Masanja H; Silva Y; Lopez MC; Kitua A
    Vaccine; 1994 Mar; 12(4):328-36. PubMed ID: 8178555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.